Canadian Continuation of Roll-over Study in Patients With Endogenous Cushing's Syndrome
Status:
Active, not recruiting
Trial end date:
2025-11-24
Target enrollment:
Participant gender:
Summary
The purpose of this study is to continue the evaluation of long-term safety of osilodrostat
in 7 Canadian patients who have already received osilodrostat treatment in a previous Global
Recordati-sponsored roll-over study and who, based on investigators' judgement, will continue
benefiting with its administration.